Work

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma

Year: 2012

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-012-9862-2

Authors: Patrick A. Ott, Richard D. Carvajal, Neeta Pandit-Taskar, Achim A. Jungbluth, Eric W. Hoffman, Bor-Wen Wu, John S. Bomalaski, Ralph Venhaus, Linda Pan, Lloyd J. Old, Anna C. Pavlick, Jedd D. Wolchok

Institutions: Harvard University, Dana-Farber Cancer Institute, New York University, Memorial Sloan Kettering Cancer Center, Ludwig Cancer Research, Ludwig Cancer Research

Language: English

Topic: Cancer Research and Treatments

Subfield: Biotechnology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Award: Cancer Center Support Grant

OpenAlex ID: W2043600567

FWCI: 8.009

Cites: 34

Cited by: 146

Related to: 10